For this issue of The Pharmacologist, we’re excited to share the stories of two prominent ASPET members and leaders in the field. In an autobiographical essay, Joan Brown, PhD, and ASPET member since 1978, writes openly about the guidance she received throughout her education, and how it informed her award-winning career. And Lori Isom, PhD, a society member since 1998, shares in an interview how community and collaboration have been crucially important in her groundbreaking research.
There is no one certain path to becoming a successful scientist, but as the journeys of Drs. Brown and Isom illustrate, each path often shares similarities—an early interest in science, education at strong and supportive programs, and inspired mentorship.
Finding a Home in Pharmacology: The Evolution of a Career
By Joan Heller Brown, PhD
Early Days
We all likely recollect, when musing about our life’s trajectory, certain curious aspects of our childhood behavior. For me such a recollection was triggered by finding compositions, stashed in my mother’s closet, from my K–12 school days in Beachwood, Ohio. One paper was entitled “Witchcraft” and another “Mental Illness in America.” Perhaps these early interests presaged my choice of the newly developed “Neurobiology and Behavior” major which I selected in my first year of college at Cornell University. One of my most inspiring courses was given by the psychologist Urie Brofenbrenner, and revealed that scientific research could be applied to explain things like why diseases developed in specific parts of the world, or why babies don’t crawl off a platform. Science, I realized, might well explain the curious aspects of behavior that had intrigued me.
In my senior year I found a path to doing laboratory research with a professor named Frank Rosenblatt. As a total novice, I was tasked with making solutions and learned, to my mortification, that no course had ever taught me what a “molar solution” was. I struggled through, but stuck with it because the lab’s research really piqued my interest. They were doing experiments to understand the biochemical basis of learning and memory. More specifically, they were using “memory transfer” experiments, in which they trained mice, ground up their brains, and fed them to naïve mice. They hypothesized that memory of a learned task (turning right or left in a maze for a reward) could be transferred to recipient mice. The most instructive moment came when, while attending their lab meeting, I learned that scientists generate new hypotheses based on observation. In this case, it was a particularly surprising observation: mice receiving the brain extract from donor mice that had been trained to turn left, actually turned right at a higher-than-expected frequency!
It seemed to me that this disproved the hypothesis but, unfazed, one of the lab members suggested an explanation, i.e., that the chemical signal to turn left was fully saturated in the brain of the donor, leading to a propensity to turn right, rather than make the normal random choice, in the recipient. I was thrilled by the notion that one could generate findings and interpret them to fit the data, and grew hooked on the idea of doing hypothesis-driven (or hypothesis-generating) research.
Falling Into Pharmacology
As my senior year was coming to an end it became evident that I had no idea how to advance my education through a graduate training program.
I wanted a biological focus on the brain, and neither the GRE exam in Psychology nor the offerings in Physiological Psychology graduate programs fit my interests. At the time, neuroscience graduate programs simply didn’t exist. A fellow student I met in the midst of my dilemma told me about research-focused graduate programs in certain medical schools; in particular, at Albert Einstein College of Medicine (AECOM). There I found a graduate program in Pharmacology, with several faculty members studying drug and neurohormone action on the brain. While I knew nothing about the discipline of Pharmacology, I realized that the actions of drugs could provide a window into understanding the molecular mechanisms underlying the behavioral systems they affected. I applied to the Department of Pharmacology at AECOM, was accepted, and matriculated into what turned out to be a loosely defined program with only 2 other students in my class, no graduate courses, and no research rotations.
On the other hand, while the curriculum given to us was largely designed for the medical students, it included advanced courses and labs in biochemistry, physiology, neuroanatomy and pharmacology… all of which I loved. The textbook for the Pharmacology course was Goodman and Gilman’s Pharmacological Basis of Therapeutics; while initially unknown to me, the chair of the Pharmacology Department was the editor of this leading scholarly work. Alfred Gilman Sr. was, additionally, a former President of ASPET, and the faculty teaching the Pharmacology course were all authors of various chapters in the book. These professors, as well as those in Biochemistry and Neuroanatomy, were superb. There was also an unusually large number of women faculty at AECOM, and I barely recognized how unique this was because they seemed to be seamlessly integrated into the mix.
Research Findings
Many of the Pharmacology faculty who had interested me initially moved to other institutions during my first year, so finding a lab for my thesis research was a challenge. I was directed to Maynard Makman, an MD/PhD who trained at Case Western Reserve with the early group who discovered the role of cyclic AMP. While he had never trained a graduate student, his lack of mentoring experience was compensated by his total engagement and excitement over my research. It also turned out that Ora Rosen, one of the extraordinary women faculty members at AECOM, gave a graduate-level course focused on various aspects of what we now think of as “cell signaling,” the only course I was offered that was intended for graduate students, and one in which we read scientific papers!
My research in the Makman Lab used the retina as a model brain slice and led to the discovery that adenylate cyclase activity could be regulated not only by epinephrine and norepinephrine, as originally determined, but also by dopamine. Intriguingly, my studies showed that dopamine stimulated cyclic AMP formation through a pathway that was not blocked by adrenergic receptor antagonists, but rather by phenothiazines and other antipsychotic drugs. This provided strong evidence regarding the developing concept that psychosis, a hallmark of schizophrenia, was mediated through changes in the properties of the (as yet undiscovered) receptor for dopamine.
Fortuitously, this observation brought me into an area of neurochemistry clearly related to brain and behavior. Moreover, it led to my first direct contact with Dr. Gilman, because Dr. Makman encouraged me to ask him to communicate our manuscript to the Proceedings of the National Academy of Science. Dr. Gilman, a rather taciturn individual, did not manifest much interest but agreed to help, perhaps because his son, the junior Alfred Gilman (Nobel Laureate, UT Southwestern) was himself working in this area, developing early in his career what became a widely used assay for cyclic AMP.
In my time at AECOM I had the privilege of also getting to know two other major figures in pharmacology, Arthur Grollman and his research associate Susan Horwitz. Susan served on my thesis committee and, although my work was far outside her area of expertise, complimented me on my thesis and has been a role model, friend, and supporter of my career ever since.
Meeting ASPET Leaders
Finding a postdoctoral position was also a fortuitous experience.
My husband and I were living in Riverdale, in the basement apartment of Eric Kandel’s home. We were supposed to be (and were) largely invisible occupants, but I did occasionally run into Dr. Kandel and took the opportunity to discuss my interests and gather his ideas about postdoctoral possibilities.
The most exciting postdoctoral interview I had was with Perry Molinoff, a new assistant professor in the Department of Pharmacology at the University of Colorado, with whom I instantly bonded. Luckily, the University of Colorado also had an excellent fellowship program in Child Psychiatry, which fit with my husband’s career plans. We were both accepted into our chosen programs, and once again, I joined a lab where my mentor did not have significant previous training experience. While I was his first postdoctoral (or other) trainee, he subsequently hired Ken Harden and Barry Wolfe and we formed an amazing gang, enjoying every minute of our time in the lab and spending our time off together, often with Perry and his wife Marlene. When my project on catecholamine metabolism led me to follow an assay developed in the laboratory of Norman Weiner, the Department Chair, I met with him and he became the second ASPET president who knew my name! Another faculty member in the Department at the University of Colorado was Chip Rutledge, the third ASPET president I had the fortune to know.
My Penultimate, and Most Opportune, Move
My husband completed his fellowship in Colorado in two years and needed to move on. I learned of a research faculty position in the division of Pharmacology at the University of California San Diego (UCSD). We had visited the city previously since our friend Larry Squire, whom I had worked with at AECOM in the lab of Sam Barondes, had moved with him to UCSD.
I joined the lab of Dr. Stephen Mayer, the fourth ASPET president on whose radar screen I appeared, as a research assistant professor in 1975. Once again, for a time I was the only research fellow in the lab, until the following year, when Larry Brunton joined as a postdoctoral fellow. While the project to which I was assigned held limited interest for me, I took on a side project related to my earlier experiences, using isolated mouse atria to study cyclic AMP signaling. Guided by Joanne Ingwall, and given total independence and flexibility by Dr. Mayer, I discovered that acetylcholine inhibited cyclic AMP formation in the heart, an explanation for parasympathetic antagonism of the sympathetic control of heart rate. I published a sole-authored paper in Molecular Pharmacology (PMID: 231196) on this topic and went on to do considerably more work on muscarinic cholinergic receptor signaling in the heart and other tissues.
On the basis of this research, I was awarded a Faculty Development Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) which put me in a position to be competitive for a faculty position at UCSD. Here Palmer Taylor became highly instrumental in my success. Palmer succeeded Steve Mayer as Pharmacology chair at UCSD, and subsequently managed to turn the Division into the Department of Pharmacology. He inspired me to teach in the medical school and graduate Pharmacology courses, attended my lectures, and encouraged me to apply for a tenure track faculty position that had become available. Then, when he became founding Dean of the Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD, he asked me to serve as the Interim chair of the Department. Additionally, I took over for him as Director of our longstanding T32 in Pharmaceutical Sciences, which I successfully helped renew for many cycles. And, continuing the theme, Palmer was still another president of ASPET who became involved in my career.
The only thing Palmer requested that I declined was to run for president of ASPET. My focus was on my lab’s research and, subsequent to being appointed as Pharmacology chair in 2004, on expanding the Department. My goal was to maintain Pharmacology as a distinct department, avoiding the mergers with other departments and concomitant loss of identity of the discipline of Pharmacology so common at the time. I was able to obtain four more FTEs, hire 15 more faculty, and grow the department’s research funding, making the Department of Pharmacology at UCSD one of the top 3 (US News and World Reports) departments in the country during my tenure. This was my tribute to the “Make Pharmacology Great” venture that Palmer was so engaged in, and which he entrusted to me.
A Sphere of Influence
There can be no question that the Pharmacology leaders I met during my journey were responsible for my success. My first grant, which made me credible as a candidate for a tenure track faculty position was, as mentioned above, from PhRMA, and recommendations from ASPET leaders were critical in my selection for this award. Likewise, when I was recommended as Editor in Chief of Molecular Pharmacology, these leaders encouraged and supported my nomination. My association with leaders and educators in Pharmacology enabled me to take on authorship of a chapter in Goodman and Gilman, and to serve as Director of UCSD’s longstanding NIH T32 in Pharmacological Sciences. Awards from ASPET (Lucchesi, Krayer, Ruffolo, Axelrod) as well as early selection as an ASPET Fellow were most certainly accomplished, not only through my research achievements, but also with help from my friends, the ASPET leaders whom I encountered in my career, and the colleagues I met through participation in the society. Being part of this society, and the larger scientific community, provided the foundation upon which my career was built.
Those who have trained in my laboratory, as well as the trainees on our Cell and Molecular Pharmacology T32, are strongly incentivized to join ASPET and attend the annual meetings. Indeed, for many years we hosted a UCSD Pharmacology Alumni reunion at the Experimental Biology Meeting. My faculty colleagues and our training grant faculty strive to ensure that our mentees appreciate the power that understanding drug action affords them for discovering disease mechanisms and developing new therapeutics. Moreover, we want them to feel, as my story has illustrated, that association with the discipline of Pharmacology provides them with a unique and supportive scientific family. Our current cadre of pharmacology colleagues truly value this, as depicted in the photo of a dinner for Kay Meier (who was a postdoctoral fellow at UCSD) as the new ASPET chair, along with ASPET Friends and Fellows. Hopefully the next generation will feel the same degree of collegiality in their association with Pharmacology.
An Interview with Lori Isom, PhD



But it wasn’t until I went to college at Washington University that I saw how far science reached. I had my first opportunity to conduct research under Dr. Al Holzer in the Department of Chemistry, an incredible but demanding mentor. Under his guidance, and because of the work we were doing, I decided that I wanted to go into research full-time but was unsure of which specialty. This was before there were umbrella programs, like PIBS at Michigan, and it was luck that I saw an advertisement on a bulletin board about pharmacology at Vanderbilt University. Pharmacology, I learned, was translational before translational was even a word. It was the synthesis of all the basic sciences to make something happen in medicine. I thought that was a fantastic approach and decided to study at Vanderbilt.
While I was a student at Vanderbilt, Dr. Bill Catterall, then the newly appointed chair of Pharmacology at the University of Washington, came to give a guest lecture in our receptors course. Bill’s lab was celebrated for its work with ion channels. I found his presentation fascinating, and applied to work in his lab as a postdoc.
Because we didn’t yet have a deep understanding of ion channel molecular biology, the work was far more complex than either of us had realized. My project focused on cloning sodium channel beta subunits from protein sequence, but this was before the Human Genome Project, and the work took years. Once, it was so disheartening that I went into Bill’s office and announced, “You do it. I quit!” Fortunately for me, he didn’t take that seriously.
I started applying for faculty jobs after I cloned SCN1B and SCN2B. Because there were three of us from Bill’s lab (all postdocs) applying for faculty positions at the same time, Bill’s thought was that we needed to divide and conquer so that we weren’t competing for the same job. For me, he recommended an advertised position in the Department of Pharmacology at the University of Michigan.
I was six months pregnant when I interviewed at Michigan, and pregnancy turned out to be the perfect litmus test. Some places where I interviewed essentially told me, “You can be a mother, or you can have a brain. One or the other.” At Ann Arbor, on the other hand, they couldn’t have been kinder or more accommodating. It was there that I learned “The Michigan Way,” which is salt-of-the-earth people doing state-of-the-art work, a fundamental trait that is still there today. Much of my success during my thirty years at the University of Michigan has been because of that culture, and it’s one I’ve tried to extend to others—to pull others up instead of closing the door behind me.
When I came to Michigan, I was invited to join a group of senior women faculty that included giants in their field, e.g. Miriam H. Meisler, PhD, and Sally A. Camper, PhD. They took new women faculty under their wings by offering informal monthly mentoring meetings, which gave us the opportunity to learn from people who had been here a long time. Their advice and approach taught me so much about mentorship, which I still use in my own lab today.
My lab director, Chunling Chen, MD, has been with me for more than 25 years. We have a philosophy that we choose graduate students whom we would consider adopting into our own families. While this philosophy has been very successful overall, occasionally it doesn’t work, or it’s not a good fit, and we encourage a student to pursue a different lab or even a different field. That can be a difficult conversation, but it’s always one those students eventually come to appreciate. Dedicating one’s life to science is not easy. Research is increasingly expensive, with narrowing opportunities. We as faculty commit our time and our funds, but students commit the most precious resource—their lives. If pharmacology isn’t the right fit, then continuing to pursue it might be devastating.
To that point, we need students who are passionate. In my lab, we’ve moved beyond pursuing “knowledge for knowledge’s sake” to “there are patients waiting.” Patients are literally waiting for our results. This ties into my work with SUDEP and Dravet syndrome. Right about the time that the Nobel Prize was given to Dr. Shinya Yamanaka for his work on induced pluripotent stem cells (iPSCs), Dr. Jack Parent, my long-term colleague in the Department of Neurology, told me that he was going to try and make iPSC neurons from patients with Dravet Syndrome. He asked if I wanted to collaborate.
My “yes” to Jack started a collaboration that has lasted years. We’ve been able to work on patient-derived iPSCs, and now we’re working on organoids and assembloids. People often ask Jack and I about the magic behind our partnership, and the truth is that Jack and I are very like-minded. We’ve never let ego get in the way of progress. We are great friends.
In collaboration with Stoke Therapeutics, may lab has developed the first gene-modifying therapy for epilepsy (Zorevunersen) that’s saving and changing patients’ lives—not only stopping seizures but also reversing the intellectual disability inherent in Dravet syndrome.
This work has led to irreplaceable moments.
In 2020, Dr. Julie Ziobro (a pediatric neurologist colleague at Michigan, and PI of the clinical trial of Zorevunersen) asked me to meet a little boy, Zane, and his mom. He was the first patient we dosed with STK-001 (Zorevunersen). I met Zane, who had gone from an average of fifty seizures a month to approximately one. He was able to attend preschool for the first time, and their family was able to go on a vacation. Typically, children with this condition can’t even dive into a pool without seizing.
But meeting that little boy… that was it. I could have retired that day. That was the greatest thing. And now when I go to Dravet syndrome patient and family meetings, and I meet the moms and dads with kids on our drug, I don’t care what else we ever do. That’s the best.


